Читать книгу Parathyroid Disorders - Группа авторов - Страница 37

1Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al: Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017;28:1–19.

2Callender GG, Udelsman R: Surgery for primary hyperparathyroidism. Cancer 2014;120:3602–3216.

3Fraser WD: Hyperparathyroidism. Lancet 2009;374:145–158.

4Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV: Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 2016;101:2284–2299.

5Wermers RA, Khosla S, Atkinson EJ, et al: The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota 1965–1992. Ann Int Med 1997;126:433–440.

6Silverberg SJ: Primary hyperparathyroidism; in Rosen CJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed 8. Washington, American Society for Bone and Mineral Research, 2013, pp 543–552.

7Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ 3rd, Wermers RA: Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 2015;73:1–7.

8Yeh MW, Ituarte PH, Zhou HC, Nishimoto S, Liu IL, Harari A, Haigh PI, Adams AL: Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013;98:1122–1129.

9Yu N, Donnan PT, Murphy MJ, Leese GP: Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol 2009;71:485–493.

10Walker MD, Silverberg SJ: Primary hyperparathyroidism. Nat Rev Endocrinol 2018;14:115–125.

11Bilezikian JP, Bandeira L, Khan A, Cusano NE: Hyperparathyroidism. Lancet 2018;391:168–178.

12Marcocci C, Cetani F, Rubin MR, et al: Parathyroid carcinoma. J Bone Miner Res 2008;23:1869–1880.

13Li Y, Simonds WF: Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer 2015;23:R229–R247.

14Tezelman S, Rodriguez JM, Shen W, Siperstein AE, Duh QY, Clark OH: Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy. J Am Coll Surg 1995;180:81–87.

15Sharretts JM, Simonds WF: Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab 2010;24:491–502.

16Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, Dempster D, Lewiecki EM, Liu JM, Minisola S, Rejnmark L, Silva BC, Walker MD, Bilezikian JP: Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3580–3594.

17Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP: Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013;98:2734–2741.

18Eastell R, Brandi ML, Costa AG, D’Amour P, Shoback DM, Thakker RV: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3570–3579.

19Zanocco KA, Yeh MW: Primary hyperparathyroidism: effects on bone health. Endocrinol Metab Clin North Am 2017;46:87–104.

20Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi P, Diacinti D, Pepe J, Piemonte S, Scillitani A, Minisola S, Bilezikian JP: Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 2015;100:1309–1315.

21Castellano E, Attanasio R, Gianotti L, Cesario F, Tassone F, Borretta G: Forearm DXA increases the rate of patients with asymptomatic primary hyperparathyroidism meeting surgical criteria. J Clin Endocrinol Metab 2016;101:2728–2732.

22Vestergaard P: Primary hyperparathyroidism and nephrolithiasis. Ann Endocrinol 2015;76:116–119.

23Marchini GS, Faria KVM, Torricelli FCM, Monga M, Srougi M, Nahas WC, Mazzucchi E: Sporadic primary hyperparathyroidism and stone disease: a comprehensive metabolic evaluation before and after parathyroidectomy. BJU Int 2018;121:281–288.

24Walker MD, McMahon DJ, Inabnet WB, et al: Neuropsychological factors in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 2009;94:1951–1958.

25Bilezikian JP, Khan A, Potts JT Jr, Brandi ML, Clarke BL, Shoback D, Jüppner H, D’Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J: Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 2011;26:2317–2337.

26Cheng Z, Zou S, Peng D, Zhang G, Zhu X: Prognostic value of ^99mTc-sestamibi parathyroid scintigraphy in predicting future surgical eligibility in patients with asymptomatic primary hyperparathyroidism. Clin Nucl Med 2018;43:151–154.

27Sun B, Guo B, Wu B, Kang J, Deng X, Zhang Z, Fan Y: Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016. Osteoporos Int 2018;29:635–642.

28Stephen AE, Mannstadt M, Hodin RA: Indications for surgical management of hyperparathyroidism: a review. JAMA Surg 2017;152:878–882.

29Consensus Development Conference Panel: Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med 1991;114:593–597.

30Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al: Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002;87:5353–5361.

31Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab 2009;94:335–339.

32Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.

33Rubin MR, Bilezikian JP, McMahon DJ, et al: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462–3470.

34Polistena A, Lucchini R, Monacelli M, Triola R, Avenia S, Barillaro I, Johnson LB, Sanguinetti A, Avenia N: Current indications for surgical treatment of primary hyperparathyroidism in the elderly. Am Surg 2017;83:296–302.

35Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard JM, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N: F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging 2018;45:658–666.

36Ajmi S, Sfar R, Trimeche S, Ben Ali K, Nouira M: Scintigraphic findings in hungry bone syndrome following parathyroidectomy. Rev Esp Med Nucl 2010;29:81–83.

37Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solórzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE: The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016;151:959–968.

38Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.

39Orr-Walker BJ, Evans MC, Clearwater JM, Horne A, Grey AB, Reid IR: Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. Arch Intern Med 2000;160:2161–2166.

40Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A: Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 2015;26:1295–1302.

41Rubin MR, Lee KH, McMahon DJ, Silverberg SJ: Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 2003;88:1174–1178.

42Peacock M, Bolognese MA, Borofsky M, et al: Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009;94:4860–4867.

Bart L. Clarke, MD

Mayo Clinic E18-A

200 1st Street SW

Rochester, MN 55905 (USA)

E-Mail clarke.bart@mayo.edu